Our RESETTM clinical trials with rese-cel (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, and pemphigus vulgaris are now recruiting.
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 03/04/25 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 03/04/25 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 03/04/25 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 03/04/25 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 03/04/25 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 02/18/25 | 8-K/A | Current report filing |
|
   |
9 |
| 02/18/25 | 8-K | Current report filing |
|
|
36 |
| 02/05/25 | SCHEDULE 13G/A | Statement of Beneficial Ownership by Certain Investors |
|
6 | |
| 01/13/25 | 8-K | Current report filing |
|
|
37 |
| 12/06/24 | SC 13G/A | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions |
|
6 |
